IVV has now cleared the $750 zone that defined the S&P 500's recovery ceiling all month — the question this week is whether the index can hold it as the biggest earnings season in years gets underway.
The ETF closed at $751.08 on July 7, up 0.3% on the week and fractionally off its recent high. That puts it squarely above the $748–$750 level that last week's note described as the contested recovery zone. The one-month gain is now 1.4%. The June 16 recovery high of roughly $751–$753 has effectively been matched. The price action is constructive, but the gap between where the market is trading and what it needs to earn to justify that level is widening — and Q2 results will start to answer that question over the next four weeks.
The lending market offers no drama here. Borrow availability for IVV is essentially unlimited — over 1.1 billion shares remain available in the lending pool, an availability reading that has been at or near its ceiling for the entire month. Short interest is a genuine rounding error at 0.59% of float, though it has ticked up 12% on the week from a very low base. Cost to borrow is 0.42%, up sharply from a month-ago reading near 0.19%, but still trivially cheap in absolute terms. None of this signals any meaningful directional conviction from short sellers. The sharp halving of short interest over the past month — down roughly 50% — confirms that whatever hedging was in place through the spring has largely been unwound.
Options positioning has shifted slightly more constructive than it was in mid-June, and that itself is the more interesting story. The put/call ratio has drifted lower to 0.90, now running a touch below its 20-day average of 0.93. That's a modest but genuine shift from the defensive reads of 1.02 seen through mid-June, when the index was selling off. The z-score of -0.22 is essentially neutral. The 52-week range for the PCR runs from 0.33 to 1.35, so current positioning is unremarkable — neither defensive nor aggressively bullish. Options traders appear to be watching, not leaning.
The institutional picture reinforces the ETF's role as a passive core holding rather than a tactical vehicle. BlackRock itself holds nearly 8% of shares — consistent with its role as fund sponsor and authorized participant. JPMorgan added aggressively in Q1, picking up 12 million shares, while Royal Bank of Canada trimmed by a similar magnitude. Marshall Wace, the London-based hedge fund, cut its position by 6.2 million shares in Q1 — a notable reduction from an active manager that typically uses ETF positions as macro hedges rather than long-term allocations. Whether that reflects a reduced macro hedge or a broader de-risking is not clear from the filing data alone.
The ORTEX short score has been remarkably stable, sitting near 26.3–26.7 for the past two weeks. That consistency reflects what the data shows: almost no short activity, abundant borrow, low cost. There is nothing in the lending or positioning data that suggests the short side is building a view on the index at these levels.
What to watch next is straightforward: Q2 earnings season opens in earnest this week, with major banks reporting first. The S&P traded at record-high forward valuations heading into this reporting period, and the gap between current price levels and consensus earnings expectations is the central tension — not borrow availability, not options skew, not insider activity.
See the live data behind this article on ORTEX.
Open IVV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
